Dare Bioscience Inc - ESG Rating & Company Profile powered by AI
This ESG assessment for Dare Bioscience Inc indicates its transparency towards the UN Sustainable Development Goals. The assessment of Dare Bioscience Inc is prepared by All Street Sevva using leading Cognitive Robots. Detailed ESG analysis of Dare Bioscience Inc can be reached by logging in.
Dare Bioscience Inc in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 2.4; made up of an environmental score of 0.0, social score of 3.2 and governance score of 4.0.
2.4
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Analytik Jena AG | 8.0 | High |
1 | Amniotics AB (publ) | 8.0 | High |
... | ... | ... | |
111 | TRYP Therapeutics Inc | 2.7 | Medium |
123 | Millennium Pharmaceuticals Inc | 2.6 | Medium |
124 | Dare Bioscience Inc | 2.4 | Medium |
124 | Karo Pharma Norge AS | 2.4 | Medium |
124 | MustGrow Biologics Corp | 2.4 | Medium |
... | ... | ... | |
182 | Wesana Health Holdings Inc | 0.0 | Low |
182 | rEVO Biologics Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Dare Bioscience Inc have an accelerator or VC vehicle to help deliver innovation?
Does Dare Bioscience Inc disclose current and historical energy intensity?
Does Dare Bioscience Inc report the average age of the workforce?
Does Dare Bioscience Inc reference operational or capital allocation in relation to climate change?
Does Dare Bioscience Inc disclose its ethnicity pay gap?
Does Dare Bioscience Inc disclose cybersecurity risks?
Does Dare Bioscience Inc offer flexible work?
Does Dare Bioscience Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Dare Bioscience Inc disclose the number of employees in R&D functions?
Does Dare Bioscience Inc conduct supply chain audits?
Does Dare Bioscience Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Dare Bioscience Inc conduct 360 degree staff reviews?
Does Dare Bioscience Inc disclose the individual responsible for D&I?
Does Dare Bioscience Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Dare Bioscience Inc disclose current and / or historical scope 2 emissions?
Does Dare Bioscience Inc disclose water use targets?
Does Dare Bioscience Inc have careers partnerships with academic institutions?
Did Dare Bioscience Inc have a product recall in the last two years?
Does Dare Bioscience Inc disclose incidents of discrimination?
Does Dare Bioscience Inc allow for Work Councils/Collective Agreements to be formed?
Has Dare Bioscience Inc issued a profit warning in the past 24 months?
Does Dare Bioscience Inc disclose parental leave metrics?
Does Dare Bioscience Inc disclose climate scenario or pathway analysis?
Does Dare Bioscience Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Dare Bioscience Inc disclose the pay ratio of women to men?
Does Dare Bioscience Inc support suppliers with sustainability related research and development?
Does Dare Bioscience Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Dare Bioscience Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Dare Bioscience Inc involved in embryonic stem cell research?
Does Dare Bioscience Inc disclose GHG and Air Emissions intensity?
Does Dare Bioscience Inc disclose its waste policy?
Does Dare Bioscience Inc report according to TCFD requirements?
Does Dare Bioscience Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Dare Bioscience Inc disclose energy use targets?
Does Dare Bioscience Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Dare Bioscience Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Dare Bioscience Inc
These potential risks are based on the size, segment and geographies of the company.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.